Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
Glaukos Corporation (GKOS)
Last glaukos corporation earnings: 2/27 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.glaukos.com/investors/investor-overview/default.aspx
Company Research
Source: Business Wire
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several positive clinical updates for its iDose® sustained-release procedural pharmaceutical platform, including:In a new 36-month follow-up analysis of its two Phase 3 pivotal clinical trials, iDose TR (travoprost intracameral implant) 75 mcg, an FDA-approved prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma, demonstrated sustained substantial IOP reductions as approximately 70% of iDose TR subjects remained well-controlled on the same or fewer IOP-lowering topical medications at 36 months after a single administration of iDose TR, versus 58% of timolol control subjects. In addition, iDose TR continued to demonstrate excellent tolerability and a favor
Show less
Read more
Impact Snapshot
Event Time:
GKOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GKOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GKOS alerts
High impacting Glaukos Corporation news events
Weekly update
A roundup of the hottest topics
GKOS
News
- Glaukos (NYSE:GKOS) had its price target raised by analysts at Truist Financial Corporation from $120.00 to $145.00. They now have a "buy" rating on the stock.MarketBeat
- Glaukos (NYSE:GKOS) was given a new $165.00 price target on by analysts at UBS Group AG.MarketBeat
- Glaukos (NYSE:GKOS) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Glaukos Announces Participation in J.P. Morgan Healthcare ConferenceBusiness Wire
- Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
GKOS
Earnings
- 10/29/25 - Beat
GKOS
Sec Filings
- 12/15/25 - Form 4
- 12/15/25 - Form 4
- 12/15/25 - Form 4
- GKOS's page on the SEC website